Food-fodder traits in groundnut

Changes in the level of GPT, BUN, and creatinine by treatment with LL28 in mice. (PDF 109 kb

Additional file 1: Figure S1. of Tracking dendritic cell migration into lymph nodes by using a novel PET probe 18F-tetrafluoroborate for sodium/iodide symporter

Schematic diagram for the in vivo monitoring of reporter DC/NF cells after their intramuscular injection. Briefly, combined BLI and 18F-TFB PET/CT imaging was performed on day 1 or 4 after the injection of DC and DC/NF cells into the right and left thighs of mice, respectively. Figure S2. Schematic diagram for the in vivo monitoring of reporter DC/NF cell migration to the DPLNs. In vivo BLI and 18F-TFB PET/CT imaging were performed on day 2 after the injection of DC and DC/NF cells in the right and left footpads of mice, respectively. Figure S3. Synthesis and characterization of 18F-TFB. (A) Schematic representation of 18F-TFB synthesis. (B) Chromatograms of radio-TLC to monitor the radiolabeling reaction. (PPTX 1047 kb

Additional file 3: Table S2. of Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

The IC50 values showing the inhibitory effect of LL28 on the viability of a panel of human lung cancer cells. (PDF 177 kb

Additional file 5: Table S4. of Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

Changes in the level of GPT, BUN, and creatinine by treatment with LL28 in mice. (PDF 109 kb

Additional file 4: Table S3. of Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R/Src inhibitor as a novel anticancer agent with minimal toxicity

The IC50 values showing the inhibitory effect of LL28 on the anchorage-dependent colony -forming ability of a panel of human lung cancer cells. (PDF 176 kb

Additional file 1: Table S1. of Association analysis of ILVBL gene polymorphisms with aspirin-exacerbated respiratory disease in asthma

Hardy-Weinberg Equilibrium of SNPs and haplotypes in ILVBL gene. (XLS 27 kb

Univariate Cox proportional hazards regression analysis for survival in various subgroups of soft-tissue sarcomas according to the expression of BRCA1, BRCA2, PARP1, and γH2AX.

<p>Univariate Cox proportional hazards regression analysis for survival in various subgroups of soft-tissue sarcomas according to the expression of BRCA1, BRCA2, PARP1, and γH2AX.</p

Expression of SIRT1 and DBC1 Is Associated with Poor Prognosis of Soft Tissue Sarcomas

<div><p>Recently, the roles of SIRT1 and deleted in breast cancer 1 (DBC1) in human cancer have been extensively studied and it has been demonstrated that they are involved in many human carcinomas. However, their clinical significance for soft-tissue sarcomas has not been examined. In this study, we evaluated the expression and prognostic significance of the expression of SIRT1, DBC1, P53, β-catenin, cyclin D1, and KI67 in 104 cases of soft-tissue sarcomas. <i>RESULTS:</i> Immunohistochemical expression of SIRT1, DBC1, P53, β-catenin, and cyclin D1 were seen in 71%, 74%, 53%, 48%, and 73% of sarcomas, respectively. The expression of SIRT1, DBC1, P53, β-catenin, and cyclin D1 were significantly correlated with advanced clinicopathological parameters such as higher clinical stage, higher histological grade, increased mitotic counts, and distant metastasis. The expression of SIRT1, DBC1, P53, β-catenin, cyclin D1, and KI67 were significantly correlated with each other and positive expression of all of these predicted shorter overall survival and event-free survival by univariate analysis. Multivariate analysis revealed the expression of SIRT1 as an independent prognostic indicator for overall survival and event-free survival of sarcoma patients. In conclusion, this study demonstrates that SIRT1- and DBC1-related pathways may be involved in the progression of soft-tissue sarcomas and can be used as clinically significant prognostic indicators for sarcoma patients. Moreover, the SIRT1- and DBC1-related pathways could be new therapeutic targets for the treatment of sarcomas.</p></div

Kaplan-Meier survival analysis of the sub-populations of soft tissue sarcomas according to adjuvant radiotherapy.

<p>Disease-specific survival and event-free survival according to the expression of PARP1, γH2AX, BRCA1, and BRCA2 in 72 soft tissue sarcoma patients who did not received adjuvant radiotherapy (A) and 40 soft tissue sarcoma patients who received adjuvant radiotherapy (B).</p

Kaplan-Meier survival analysis in soft tissue sarcomas.

<p>Disease-specific survival and event-free survival according to the expression of PARP1, γH2AX, BRCA1, and BRCA2.</p